Type 1 Diabetes
Desperate unmet need to prevent the morbidities of brain injury – Aneurysmal Subarachnoid Hemorrhage (aSAH)
In type 1 diabetes, the pancreas stops making insulin.
- Diabetes mellitus is at epidemic levels and its trajectory continues to rise worldwide, with Type 1 diabetes (T1D) accounting for 5-10% of all diabetes cases.1 T1D develops on the basis of immune and inflammatory destruction of pancreatic beta islet cells, with the progression being described in 3 stages.
- ALOX12 is a major contributor to beta cell inflammation and genetic deletion of 12-LOX in mouse models prevents diabetes development. The first generation ALOX12 inhibitor prevented the progression of the disease. We have now generated a 2nd generation inhibitor with superior IP, potency and oral availability. Tzeild, given by IV infusion for 14 days continuously, is effective in only 20% of patients. We see an opportunity for an oral cost effective alternative to prevent or reverse beta cell decline in T1D patients and to reduce major complications of diabetes.
ALOX12 upregulated in human b islet cells of
T1D and T2D pancreas
LX12001 prevents the progression of T1D
and rescues b islet cells in human pancreas
- ALOX12 KO mice prevents T1D development.
- Specific inhibition of ALOX12 stops the progression of T1D and preserved beta islet cell function.
- Completed screening and ADMET studies for LX12001.